Intelligence / Healthtech / New Clinical Trials / CSPC-NBP Pharmaceutical Co., Ltd.
CSPC-NBP Pharmaceutical Co., Ltd.
12 Nov 2026: Trial registered · A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 12 Nov 2026
- Title
- A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07933133
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at CSPC-NBP Pharmaceutical Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.